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Abstract
Background Mucolipidosis type III α/β or γ (MLIII) are rare autosomal recessive diseases, in which reduced activity of the
enzyme UDP-N-acetyl glucosamine-1-phosphotransferase (GlcNAc-PTase) leads to intra-lysosomal accumulation of different
substrates. Publications on the natural history of MLIII, especially the milder forms, are scarce. This study provides a detailed
description of the disease characteristics and its natural course in adult patients with MLIII.
Methods In this retrospective chart study, the clinical, biochemical and molecular findings in adult patients with a confirmed
diagnosis of MLIII from three treatment centres were collected.
Results Thirteen patients with MLIII were included in this study. Four patients (31%) were initially misdiagnosed with a type of
mucopolysaccharidosis (MPS). Four patients (31%) had mild cognitive impairment. Six patients (46%) needed help with activities of
daily living (ADL) or were wheelchair-dependent. All patients had dysostosis multiplex and progressive secondary osteoarthritis,
characterised by cartilage destruction and bone lesions inmultiple joints. All patients underwentmultiple orthopaedic surgical interven-
tions as early as the second or third decades of life, of which total hip replacement (THR) was the most common procedure (61% of
patients). Carpal tunnel syndrome (CTS)was found in 12 patients (92%) and in eight patients (61%), CTS release was performed.
Conclusions Severe skeletal abnormalities, resulting from abnormal bone development and severe progressive osteoarthritis, are
the hallmark ofMLIII, necessitating surgical orthopaedic interventions early in life. Future therapies for this disease should focus
on improving cartilage and bone quality, preventing skeletal complications and improving mobility.
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Introduction
Mucolipidoses type II/III α/β or γ (MLII OMIM#252500,
MLIII α/β MIM#252600, MLIII γ OMIM#252605) are
rare autosomal recessive diseases (Maroteaux and Lamy
1966; Leroy and Martin 1975; Raas-Rothschild et al.
2000, 2004; Cathey et al. 2008, 2010). In these condi-
tions, activity of the membrane-bound hexameric enzyme
UDP-N-acetyl glucosamine-1-phosphotransferase
(GlcNAc-PTase), consisting of three subunits named α2,
β2 and γ2, is absent or reduced (Reitman and Kornfeld
1981; Bao et al. 1996; Raas-Rothschild et al. 2000; Kudo
et al. 2005; Tiede et al. 2005). The GNPTAB gene (chro-
mosome 12q23.3; OMIM#607840) encodes for the α/β
subunits and the GNPTG gene (chromosome 16;
OMIM#607838) for the γ subunits. GlcNAc-PTase is re-
sponsible for the first step in the phosphorylation of
enzyme-conjugated mannose residues to mannose-6-
phosphate in the Golgi apparatus. Mannose-6-phosphate
serves as the recognition marker, targeting newly synthe-
sised lysosomal enzymes to the lysosome. In the absence
or reduced presence of this marker, lysosomal enzymes
are secreted in plasma, where they are unable to execute
their function (Reitman and Kornfeld 1981), resulting in
the accumulation of several substrates, such as glycosami-
noglycans and (glyco)sphingolipids.
ML presents as a clinical spectrum. In the most severe
form, MLII (OMIM#252500, I-cell disease), GlcNac-PTase
activity is completely deficient, leading to severe and rap-
idly progressive airway, cardiac, skeletal and nervous sys-
tem disease, resulting in death in early childhood (Leroy
and Martin 1975; Cathey et al. 2008, 2010). MLIII α/β
has a broader phenotypic range, from severely affected
patients that die in childhood to milder affected patients
displaying primarily skeletal symptoms, who survive into
adulthood (Maroteaux and Lamy 1966; Bargal et al. 2006;
Encarnação et al. 2009; Otomo et al. 2009; Cathey et al.
2010; David-Vizcarra et al. 2010; Yang et al. 2017). The
patients with MLIII γ that have been described so far all
have milder phenotypes (Raas-Rothschild et al. 2000,
2004; Falik-Zaccai et al. 2003; Persichetti et al. 2009;
Liu et al. 2014; Tüysüz et al. 2018).
Clinical features that have been described in MLIII are
mild coarsening of the face, corneal clouding, mild reti-
nopathy, cardiac valve abnormalities, restrictive pulmo-
nary function, tracheal/bronchial malacia, skeletal dyspla-
sia, scoliosis, stiffness of the joints, short stature, claw
hand deformity, carpal/tarsal tunnel syndrome and spinal
co rd compres s ion (Haddad e t a l . 1997 , 2000 ;
Hetherington et al. 1999; Robinson et al. 2002; Raas-
Rothschild et al. 2004; Steet et al. 2005; Cripe et al.
2009; Encarnação et al. 2009; Otomo et al. 2009; Smuts
et al. 2009; Cathey et al. 2010; David-Vizcarra et al.
2010; Kerr et al. 2011; Kobayashi et al. 2011; Liu et al.
2014, 2016; Pantoja Zarza and Diez Morrondo 2014).
Reports on intellectual performance and learning abilities
vary from normal to mild cognitive impairment (Ward
et al. 1993; Umehara et al. 1997; Raas-Rothschild et al.
2004; Tiede et al. 2005; Cathey et al. 2010; Kerr et al.
2011; Kobayashi et al. 2011; Cavalcante et al. 2012; Yang
et al. 2017; Tüysüz et al. 2018). Publications on the nat-
ural history of adult MLIII patients are rare. Some single
case studies or small case series of MLIII patients
reaching adulthood have been published, but they lack
systematic description of disease onset, progression over
time and severity of the disease characteristics and surgi-
ca l intervent ions (Raas-Rothschi ld et a l . 2004;
Encarnação et al. 2009; Otomo et al. 2009; Cathey et al.
2010; David-Vizcarra et al. 2010; Yang et al. 2017;
Tüysüz et al. 2018).
Currently, there are no curative treatments for MLII
and III. From experience in other extremely rare disorders
(e.g. mucopolysaccharidosis, MPS) for which therapy be-
came available, we recognise the importance of natural
history data collection, especially of the milder cases,
since the focus in the medical literature is often on the
severe phenotypes. Once treatment becomes available, the
latter may lead to an overestimation of treatment effect, as
the course of the treated patients that are mildly affected is
compared to severely affected patients reported in the lit-
erature. Natural history studies help to identify future
therapeutic goals, aid counselling and provide the basis
for tailored standardised follow-up of these patients. The
aim of this study is to provide a detailed description of the
disease characteristics of MLIII and its natural course, by
studying data from adult patients.
Methods
Patients
In this retrospective medical record review, the clinical,
biochemical and molecular findings from adult patients
with a confirmed diagnosis of MLIII from three specialist
centres were collected [the Academic Medical Center
(AMC), Amsterdam, the Netherlands, Erasmus MC,
Rotterdam, the Netherlands and the National Hospital for
Neurology and Neurosurgery, London, United Kingdom).
The diagnosis of MLIII was established by the measurement
of plasma and/or fibroblast activity of several lysosomal en-
zymes, including β-hexosaminidase A, β-hexosaminidase A+
B, α-L-fucosidase, β-D-glucuronidase, α-D-mannosidase and
β-D-galactosidase. In addition, in a subset of patients, GlcNAc-
1-PTase activity in fibroblasts was measured or DNA analysis of
the GNPTAB or GNPTG genes was performed.
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Data on the demographic and general characteristics
(age of initial/correct diagnosis and anthropometry), clin-
ical symptoms, cognitive ability, highest education quali-
fication, impairments in activities of daily living (ADL),
wheelchair dependency, in employment, imaging results
(radiographs and MRI scans), number and types of ortho-
paedic surgeries performed and echocardiography, pulmo-
nary function tests, were collected from patient records.
Results
Patients’ characteristics
The characteristics of the 13 adult patients are outlined in
Table 1. Median age at last follow-up was 30 years (range
18–68 years). Most patients were of Caucasian descent,
and both genders were equally represented. Patients 9, 11
and 10, 12 are siblings. Out of the 13 patients, one was
initially misdiagnosed as MPS II and three as MPS IV. In
one of these patients, diagnosed with MPS IV at the age
of 30 years, the correct diagnosis was established as late
as age 64 years.
Most patients developed clinical symptoms in the first
decade of life. The diagnosis of ML was made in ten
patients by the establishment of elevated levels of lyso-
somal enzymes in plasma, confirmed by a concomitant
decreased lysosomal enzyme activity in fibroblasts in four
patients (in one patient, only enzyme measurements in
fibroblasts were performed) and in one patient by a de-
creased activity of GlcNAc-1-PTase. In seven patients,
DNA analysis was performed; three patients had muta-
tions in the GNPTAB gene and four patients in the
GNPTG gene. The mutations and clinical features of pa-
tient number 2 were published 13 years ago by Raas-
Rotschild et al. (2004). The GNPTAB gene c.1178A>G;
p.(His393Arg) mutation (patient number 1), the GNPTG
gene homozygous variants c.411 + 9_411 + 35del27 (pa-
tient number 3) and c.318-1G>C (patient numbers 6 and
7) and the GNPTG gene heterozygous mutation
c.122_138del; p.(Pro41fs) with the c.331T>C variant (pa-
tient number 5) have not been published before.
Clinical signs and functioning in daily life
Five patients had notably short statures (range 129–
158 cm, median 145 cm) (Table 2). In patient number
13, height could not be measured. Six patients needed
help with ADL and/or were wheelchair-dependent. All
but one patient suffered from carpal tunnel syndrome
(CTS) (Supplemental Table 2).
Four patients had mild cognitive impairment (patient
numbers 4, 5, 10 and 13), while cognitive function was
normal in the other nine patients (Table 2). Ten patients
were employed at any time during their adult life.
Pregnancies with healthy offspring were reported in two
patients (patient numbers 3 and 11).
Table 2 Anthropometry, cognitive involvement and functioning in daily life
Patient Height (cm) and BMI
(kg/m2) at last follow-up
Cognitive
impairment (Y/N)
Highest education
qualifications
Impairment in ADL/
wheelchair user (Y/N)
In employment
(Y/N)
1 129 (16) N Secondary education N/Y* Y
2 171 (24) N Academic education N/N Y
3 144 (28) N Secondary education N/N y
4 170 (24) Y, mild [IQ 65] Secondary education N/N Y
5 170 (22) Y, mild Special needs education Y/N N#
6 176 (33) N Professional education Y/N^ Y
7 150 (52) N N.A. Y/Y (from age 23 years onwards) Y
8 145 (24) N University Y/Y Y
9 179 (23) N University N/N Y
10 169 (29) Y, mild [IQ 70] Secondary school N/N N
11 158 (21) N College N/N Y
12 160 (20) N (OCD, depression) Secondary school N/N N
13 + Y, mild College (assisted) Y/Y N
Y; yes, N; no, IQ: intelligence quotient, ADL: activities of daily living, *can walk 400 m without a wheelchair, #: was previously employed, ^: rollator-
dependent, + height could not be measured (wheelchair-dependent for many years), weight 45 kg
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Skeletal pathology
The most prominent clinical signs were the skeletal ab-
normalities. All patients had abnormally shaped bones
(dysostosis multiplex) and progressive osteoarthritis,
characterised by cartilage destruction in joints and areas
of radiolucency in bones that may reflect erosive bone
lesions (Supplemental Table 1). These abnormalities were
found on X-rays of the hand, feet, shoulders, elbows,
hips , knees and spine (Freis inger et a l . 1992;
Hetherington et al. 1999; Haddad et al. 2000; Robinson
et al. 2002; David-Vizcarra et al. 2010; Pantoja Zarza
and Diez Morrondo 2014; Kadar et al. 2017). In four
patients, the carpal and/or tarsal bones were hypoplastic,
with secondary osteoarthritic changes observed in the
older patients (examples in Fig. 1a and Supplemental
Table 1). In 11 patients, the same abnormalities were
seen in the humeral/ femoral heads and femoral neck
(examples in Fig. 1a, b). In all patients of whom data
on hip morphology were available (n = 9), hip dysplasia
and altered pelvic shape were present (examples in Fig.
1b). Abnormalities of the spine were present in all pa-
tients; the most common findings were atypically shaped
vertebrae (hypoplasia), subluxation and scoliosis
(examples in Fig. 1a). The majority of patients reported
pain of the glenohumeral joints, and/or the hands, feet,
hips, knees and the lumbar spine. In six patients, signs of
spinal cord or nerve root compression were present
(Supplemental Table 1).
Figure 1a shows exemplary radiographs of the skull,
spine, shoulder, elbow, knee, hand, ankle and foot of three
MLIII patients (patient numbers 4, 5 and 7) at the ages of
18, 28 and 65 years, respectively. The findings in these
radiographs are described in the legend of Fig. 1a.
Separately, X-rays of the pelvis of four MLIII patients
(patient numbers 1, 5, 6 and 7) over time are shown in
Fig. 1b. In all patients, there is severe hip dysplasia, with
flaring of iliac wings as well as significant ossification
disorders of the femoral heads, with arthritic changes of
the hips. In the most severely affected patient (patient
number 1), there is near total destruction of the femoral
heads by the age of 11 years. In contrast, in patient num-
ber 5, the femoral heads are hardly affected at the age of
8 years, but by the second decade of life, severe osteoar-
thritis of both hips had developed.
The oldest patient (patient number 7) was completely
wheelchair-dependent from the age of 23 years. In this
patient, no surgical hip interventions have been per-
formed, for unknown reasons. The femoral heads were
abnormally shaped, with severe secondary osteoarthritis.
This is also seen on macroscopic and histopathological
examination of the left hip, which was removed after her
death at the age of 69 years (Fig. 1b), when she
succumbed to metastatic bladder cancer.
Orthopaedic surgical interventions and medical
treatment
For all patients, the type of orthopaedic surgeries and age
at which these were performed are depicted in Fig. 2.
Details of the specific surgical procedures can be found
in Supplemental Table 2. The most frequent intervention
was hip surgery, performed in eight patients, with first
interventions in the second or third decades of life. In
all of these patients, total hip replacement (THR) was
eventually required.
Eight patients underwent bilateral CTS release, mostly
in the second decade of life. In one patient, this interven-
tion was performed more than once. Less frequently, sur-
gical interventions of the knees, feet and spinal cord were
performed. Several patients were treated with repeated
corticosteroids injections in the glenohumeral or knee
joint to reduce pain. Two patients were treated with
bisphosphonates at their last outpatient visit (patient num-
bers 8 and 10).
Cardiac and pulmonary examinations
Echocardiography was performed in 12 patients
(Supplemental Table 3). In patient number 4, there were
limited signs of cardiac hypertrophy, with thickening of
the posterior left ventricular wall. Systolic ventricular
function was normal in all patients. Mild dilated right
ventricle with normal systolic function was seen in patient
number 10. Five patients (patient numbers 1, 4, 5, 10 and
13) had mild regurgitation of one or more valves (mitral,
aortic, pulmonary or tricuspid) and one patient had mod-
erate stenosis and regurgitation of the aortic valve (patient
number 5). None of the patients had required valve re-
placement at the time of their last follow-up.
Pulmonary function tests were performed in six patients
(Supplemental Table 3). Two patients had mild to moder-
ate restrictive lung disease (patient numbers 1 and 4).
Discussion
This multi-centre retrospective medical record review de-
scribes the clinical course of adult forms of MLIII. About
half of the patients experienced significant physical limi-
tations, being either wheelchair-dependent and/or needing
help with ADL. Pain was reported by all patients.
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Approximately one-third of the patients had mild cogni-
tive impairment. Three-fourths of patients had been
employed at any time during adulthood.
All patients have extensive skeletal pathology, requir-
ing orthopaedic surgical interventions as early as the
second or third decades of life. THR was the most
common intervention, performed in 67% of all patients.
In three patients, this was preceded by femoral varus
osteotomy, but despite this position correction, these pa-
tients still needed THR some 10 years later (Fig. 1b,
Supplemental Table 2).
As is seen in the different forms of MPS, abnormal
bone development (dysostosis multiplex) (Maroteaux
and Lamy 1966) is uniformly present in MLIII patients.
Clinically, the earliest disabling feature is hip disease,
characterised by pain and limited mobility. Abnormal
hip morphology (acetabula, iliac bones and femoral
heads) has been observed in very young MLIII patients
[at birth and at ages 4 and 6 years (Hetherington et al.
1999; Cathey et al. 2010; David-Vizcarra et al. 2010)],
suggesting early developmental alterations such as seen
in, for example, MPS VI (Oussoren et al. 2017).
In addition to the dysostosis multiplex, throughout life,
the joints in MLIII are affected by rapidly progressive
osteoarthritis, resulting in cartilage destruction and bone
lesions (areas of radiolucency and sclerosis). Clinically,
all patients suffer from bone and joint pain.
Bone disease in MLIII may arise from an imbalance
between bone-forming osteoblasts and bone-resorbing os-
teoclasts, caused by the increased presence of osteoclastic
enzymes in the bone-resorbing zone in osteoclasts
(Kollmann et al. 2013). Mannose-6-phosphate is impor-
tant for the trafficking of these enzymes along the
exocytic pathway to the apical membrane, where they
are secreted in the bone-resorbing compartment (Baron
et al. 1988). The absence of mannose-6-phosphate on
the osteoclastic enzymes may lead to increased secretion
of these enzymes, resulting in uncontrolled bone and car-
tilage degradation (Barriocanal et al. 1986; Robinson
et al. 2002). However, this hypothesis still needs to be
substantiated by pathophysiological studies.
CTS was highly prevalent in our MLIII patient popu-
lation (11 out of 13 patients) and bilateral CTS release
was performed in eight patients. Cardiac valve abnormal-
ities were found in six patients; there were no signs of
cardiac dysfunction. Six patients underwent formal pul-
monary function assessment and two patients had moder-
ate to mild restriction, most likely due to thoracic skeletal
abnormalities. No remarks concerning airway infections
or pulmonary complaints were present in the medical re-
cords. This distinguishes this condition from the different
forms of MPS (e.g. types I, II, IV and VI), in which
cardiac and pulmonary problems are more frequent, often
Fig. 1 Skeletal radiographs. a Examples of threeMLIII patients, aged 18,
28 and 65 years (patient numbers 4, 5, and 7). Skeletal radiographs of the
skull (anterior posterior and lateral), spine (thoracic/lumbar vertebrae AP
and lateral), left shoulder (AP), left elbow (lateral), left knee (AP), left
hand (AP) and left ankle/foot (AP and or lateral). In general, the devel-
opmental bone abnormalities were present in all patients, but the presence
and severity of osteoarthritic changes were more prominent in the older
patients. Skull: In all patients, thickened cortical bones and a prominent
sella turcica were observed. Open skull sutures in patient numbers 4 and
5. Dens aspect of the skull vault in patient number 7. Spine: Mild convex
right-sided scoliosis, with increased kyphosis and increased
interpedicular distances in all three patients. Flattened corpora vertebrae
on several levels (cervical, thoracic and lumbar) in all three patients.
Osteoarthritic changes of the endplates of the corpus vertebrae, most
prominent in the oldest patient (patient number 7). In patient 7, there is
anterior displacement of vertebrae L3 and L4 with a decreased diameter
of the spinal cannel. Shoulder and elbows: In patient number 4, no
abnormalities of these joints were observed. Osteoarthritic changes in
the humeral head, glenoid and elbow deformation were seen in patient
numbers 5 and 7. Knee: From patient number 4, no lateral left knee
radiograph was available. In patient number 5, there is a patella baja
and signs of osteochondral abnormalities of the patella with osteophyte
formation. In patient number 7 (X-ray performed at age 60 years), oste-
oarthritic changes were observed with lateral hook formation/bone for-
mation of the tibia plateau and at the lateral femur condyle. Hand:
Abnormal shaped phalanges in all three patients (subtle in patient number
4). Osteoarthritic changes of the phalangeal joints (proximal and distal) in
patient numbers 5 and 7. Abnormal shaped metacarpal bones (hypoplasia
and collapse) with secondary osteoarthritis (patient numbers 5 and 7).
Ankles/feet: In patient number 4, no abnormalities of the joints were
observed. In patient number 5, there is osteoarthritis of the distal fibula.
Suggestion for bifida talus or talus bipartite. Severe osteoarthritis of the
ankle is seen in patient number 7. b Radiographs, macroscopy and histo-
pathology of the hip bones. X-rays of the hips of patient numbers 1, 5, 6
and 7 over different ages. Macro- and microscopic photographs of the left
hip of patient number 7 are shown. This patient died at the age of 69 years
from metastatic bladder cancer. The most prominent findings on radio-
graphs: Pelvis: In all patients, the pelvic bones are abnormally shaped,
with flared iliac wings with hypoplasia of the inferior part of the ilea. The
acetabula are severe dysplastic, very steep and shallow. Neoacetabulum
formation occurred in patient numbers 5, 6 and 7. Impingement of the
coxofemoral spaces was seen in patient number 7. Femoral heads, neck
shaft angle: Severe ossification disorders and severe secondary osteoar-
thritis of the femoral heads (with subchondral cysts, sclerosis and flatten-
ing in patient numbers 5, 6 and 7) were present in all patients. In patient
number 1, at age 11 years, there was near total absence of the femoral
heads. Femoral shaft angle abnormalities; in patient number 1, the shaft
angle over time develops from coxa valga to coxa vara. In patient number
5, there is a coxa valga and in patient number 7 coxa vara. On autopsy in
patient number 7, part of the left femur, femoral head and part of the
acetabulum were removed, shown on the macroscopic photo. The femo-
ral head (shown from above); severe osteoarthritis is present, with com-
plete destruction of the cartilage. An arrow on the top of the femoral head
shows yellow coloured bone tissue and not the normal glossy blue-white
in appearance cartilage. Total destruction of cartilage is also illustrated by
the histological slides of the upper part of the femoral head coloured with
HE, magnification ×25 and ×100. A square on the ×25 magnification
indicates the location of the ×100 magnification. No cartilage remains
at the location of the asterisk on the ×100 magnification. Surgical inter-
ventions of the hip: Patient number 1: custom-made total hip replace-
ment (THR) of the left and right hips at 20 and 21 years, respectively.
Patient number 5: femoral varus osteotomy at ages 22 years (left hip) and
24 years (right hip) and THR at age 30 years. Patient number 6: femoral
varus osteotomy at ages 22 years (left hip) and 24 years (right hip) and
THR at 31 years (left hip) and 37 years (right hip)
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with severe clinical implications, also in the milder adult
forms of these disorders (Brands et al. 2013; Clark et al.
2017; Rapoport and Mitchell 2017).
Future therapies
Future therapies for MLIII should aim to improve bone
metabolism, in order to reduce bone pain, delay the need
for surgical intervention and improve mobil i ty.
Bisphosphonates are given in MLIII patients to decrease
osteoclastic activity, with variable outcomes (Robinson
et al. 2002; Zolkipli et al. 2005; Kerr et al. 2011;
Kobayashi et al. 2011). Since the long-term use of these
drugs suppresses bone turnover and may have a negative
effect on length growth, they may be of limited use in
MLIII. A newer anti-bone resorption drug, Denosumab
(blocking the osteoclast activating cytokine receptor acti-
vator of NFκB ligand), may hold promise for the treat-
ment of ML and has already been used with some suc-
cess in osteogenesis imperfecta, improving both growth
and vertebral shape (Hanley et al. 2012, 2017; Shaker
et al. 2015). Another option for treatment may be reduc-
tion of inflammation, by drugs such as pentosan
polysulfate (PPS), which has been shown to improve
range of motion and reduce pain in MPS I patients
(Hennermann et al. 2016). Future pathophysiological
studies on the characteristics of bone metabolism in
MLIII will be needed in order to establish the most prom-
ising therapeutic option in this disease.
Conclusion
Severe skeletal abnormalities, resulting from abnormal
bone development and severe progressive osteoarthritis,
are the hallmark of mucolipidosis type III (MLIII), neces-
sitating surgical orthopaedic interventions early in life.
Future therapies for this disease should focus on improv-
ing cartilage and bone quality, preventing skeletal compli-
cations and improving mobility.
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